Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)

NCT04243278 is registered in ClinicalTrials.gov with Dr. Graeme Smith as lead sponsor.

NCT NCT04243278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04243278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)
Lead sponsor
Dr. Graeme Smith
Phase
Phase 1
Overall status
Terminated
Start date
September 14, 2020
Completion date
December 31, 2022
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, preeclampsia severe, primary prevention